Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates

Core Viewpoint - Absci Corporation (ABSI) reported a quarterly loss of $0.24 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.19, indicating a negative earnings surprise of -26.32% [1] Financial Performance - The company posted revenues of $0.59 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 74.44%, compared to revenues of $1.27 million in the same quarter last year [2] - Over the last four quarters, the company has only surpassed consensus EPS estimates once [2] Stock Performance - Absci Corporation shares have increased by approximately 8.8% since the beginning of the year, outperforming the S&P 500's gain of 8.4% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.13 on revenues of $9.2 million, and for the current fiscal year, it is -$0.68 on revenues of $15.19 million [7] - The estimate revisions trend for Absci Corporation was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Absci Corporation belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, suggesting that the industry outlook may negatively impact stock performance [8]